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ate-life depression,defined as a major depres-
sive episode occurring in older adults (usually after the
age of 60 or 65 years),is a heterogeneous mood disorder
frequently associated with cognitive impairment.Late-
life depression encompasses both late-onset cases as well
as early-onset cases that recur or continue into later years
of life.The temporal association between cognitive and
depressive symptoms in elderly patients varies widely,yet
increasing evidence suggests that depressive illness con-
tributes to the development of persistent or progressive
cognitive deficits in some individuals.
The neurobiologic mechanism(s) underlying this link
between depression and future cognitive decline are
poorly understood. The gross and microscopic neu-
ropathology of dementia associated with depression is
highly variable,and it is has become evident that mixed
pathophysiologies are very common.
1 Moreover,certain
person-specific characteristics such as educational attain-
ment and lifestyle factors may influence the timing of
clinical dementia presentation,regardless of the nature
and extent of pathology.
Our goals in this review are to (i) summarize evidence
for the notion that prior depression increases risk of sub-
sequent cognitive decline and dementia, especially
Alzheimer’s disease (AD);(ii) outline the biological sub-
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There is a strong association between late-life depres-
sion, cognitive impairment, cerebrovascular disease, and
poor cognitive outcomes, including progressive demen-
tia, especially Alzheimer’s disease. While neuroimaging
evidence suggests that cerebrovascular disease plays a
prominent role, it seems that depression alone may also
confer substantial risk for developing Alzheimer's dis-
ease. The relationships between the prominent cere-
brovascular changes, other structural abnormalities, spe-
cific forms of cognitive dysfunction, and increased risk
for developing Alzheimer’s disease among those with
late-life depression have been difficult to reconcile. The
varied findings suggest that there are likely multiple
pathways to poor cognitive outcomes. We present a
framework outlining multiple, non-mutually exclusive
etiologic links between depression, cognitive impair-
ment, and progressive decline, including dementia.
Importantly, the model is both testable and falsifiable.
Going forward, using models such as this to inform
research should accelerate knowledge acquisition on the
depression/dementia relationship that may be useful for
dementia prevention, monitoring the impact of depres-
sion treatment on clinical status and course of illness.    
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:345-357.strates proposed to mediate this association;and (iii) use
the concepts of brain and cognitive reserve to integrate
existing evidence into linked pathways connecting
depression to AD.
Does depression increase risk of subsequent
cognitive decline and dementia?
Clinical,case-control,and epidemiologic studies show an
association between late-life depression and persistent
cognitive deficits,and between history of depression and
subsequent dementia,especially AD.Studies of late-life
depression generally find significant cognitive impair-
ment concurrent with affective symptoms,(eg,refs 2,3)
that is mediated almost entirely by slowed information
processing
3-5 or working memory deficits.
5The cognitive
deficits accompanying late-life depression often persist
following treatment and remission of affective symp-
toms.
5-8 One year after good treatment response for a
major depressive episode, significant impairment was
found in 23% of subjects who had been deemed cogni-
tively intact while depressed.
9
Two recent meta-analyses found that a history of depres-
sion approximately doubles an individual’s risk of subse-
quent dementia in general
10 and AD in particular.
11Yet,
many large individual studies have found no such rela-
tionship,giving rise to varying conclusions regarding the
temporal and directional association between depression
and mild cognitive impairment (MCI) and/or dementia.
12,13
That is,it is not clear whether prior depression is a true eti-
ologic risk factor for dementia or rather represents a pro-
dromal clinical manifestation of dementia neuropathology.
Some evidence suggests that risk for both MCI and
dementia is proportionate to cumulative depression bur-
den in terms of symptom severity, lifetime duration of
depression, or number of major depressive episodes
(MDEs).In the Cardiovascular Health Study,severity of
depressive symptoms independently predicted diagnosis
of MCI 6 years later.
14A large Danish case-registry study
found the number of prior MDEs predicted dementia
diagnosis, with a hazard ratio increasing by 13% per
MDE.
15 Finally,several studies
16-18 suggest the longer the
interval between onset of first depressive episode and
time of assessment for dementia,the greater the risk of
dementia (also see meta-analyses in refs 10,11).Overall,
the weight of available evidence suggests that depression,
including related pathophysiologic processes,may act as
a true risk factor for MCI and dementia.However,there
is no consensus as yet on this point.
Other studies have found that the shorter the interval
between depression onset and assessment for dementia,
the greater the risk,
19-21 while others found no such rela-
tionship between depression and cognitive impairment
22
or subsequent dementia.
12,23,24 Such findings suggest that
when depressive and cognitive symptoms appear close in
time they likely arise from common neuropathologic
processes.This is an important competing hypothesis to
the concept of depression as a risk factor for dementia.
Overall, these findings emphasize the heterogeneity of
late-life depression,its cognitive manifestations,and pos-
sible cognitive sequelae. Many authors emphasize the
importance of determining whether depression is a true
risk factor versus an early symptom occurring in the pro-
dromal phase of dementia,particularly AD.Substantial
support exists for both hypotheses, and they are not
mutually exclusive. This report does not resolve this
issue; rather, we review evidence for several specific
pathways by which depression may be linked to subse-
quent cognitive decline and dementia and present two
related models that accommodate and reconcile many
of the seemingly disparate research findings.One model
is shown in Figure 1 and presents three interacting links
which affect brain and cognitive reserve thereby mod-
erating the relationship between underlying AD neu-
ropatholgy and its expression as clinical dementia.In the
sections that follow we discuss the evidence for each of
the pathways and links.
Neurobiologic substrates mediating the
depression-cognitive decline-dementia links
Glucocorticoids contribute to hippocampal atrophy
and learning/episodic memory impairment
Depression is associated with neuroendocrine changes
similar to those observed in animal models of chronic
stress,including abnormalities within the hypothalamic-
pituitary-adrenal (HPA) axis. Most notably, depressed
Clinical research
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Selected abbreviations and acronyms
AD Alzheimer's disease
CAD coronary artery disease
HPA hypothalamic-pituitary-adrenal
MCI mild cognitive impairment
MDE major depressive episode
WMH hyperintense white matter regionssubjects have been shown to exhibit increased HPA cen-
tral drive with elevated corticotrophin-releasing hormone
(CRH) and vasopressin production by cells of the hypo-
thalamic paraventricular nucleus (PVN);impaired nega-
tive feedback regulation due to decreased expression of
corticosteroid receptors in the hypothalamus and pitu-
itary as well as upstream CNS regulatory centers; and
adrenal hypertrophy (reviewed in ref 25).The net effect
of these changes in HPA function is chronic elevation of
adrenal glucocorticoid production with impaired negative
feedback and abnormal homeostatic regulation. Such
HPA dysregulation is clinically detectable (via dexam-
ethasone nonsuppression or elevated 24-hour urinary cor-
tisol) in about half of patients with major depression.
25,26
HPA dysregulation may be more common among older
depressed individuals,as suggested by the finding of a sig-
nificant correlation between age and post-dexamethasone
cortisol levels in individuals with late-life depression.
27
Adrenal glucocorticoid/cortisol regulates HPA activity
through both direct negative feedback at the pituitary
and hypothalamus and indirect mechanisms involving
higher central nervous system (CNS) centers.The human
hippocampus, for example, contains large numbers of
corticosteroid receptors and plays a critical role in down-
regulating CRH release via a multisynaptic pathway ter-
minating in γ-aminobutyric acid (GABA)-ergic output to
the paraventricular nucleus (reviewed in ref 28).At the
same time,HPA disturbances causing prolonged hyper-
cortisolemia may promote hippocampal atrophy and
functional decline,such that HPA regulation is further
compromised. This interaction may underlie the
observed association between hypercortisolemic disease
states such as Cushing’s syndrome and depression,and
both hippocampal atrophy and impairment in the verbal
and spatial memory functions subserved by the hip-
pocampus.
29,30
Animal studies suggest that high-stress conditions or
exogenous glucocorticoids can cause hippocampal neu-
ronal damage
31 and memory impairment.
32These changes
have been observed concurrent with stress or exogenous
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Figure 1. Proposed predominant mechanisms by which depression increases risk for Alzheimer’s dementia (AD). 
*The very recently postulated direct pathway leading from hypercortisolemia or elevated glucocorticoids to AD neuropathology is represented
with a dashed line because, while evidence is growing, it has at present relatively less support than the other proposed pathways.
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↓ Brain/cognitive reserveglucocorticoid administration, and appear to progress
over a lifetime of stress or glucocorticoid excess (see
review in ref 33).Human studies in older adults likewise
suggest that hippocampal size and function are dimin-
ished in the setting of elevated glucocorticoids,
34,35 and in
proportion to duration of prior hypercortisolemia.
36
On the basis of these findings,many have hypothesized
that glucocorticoids may promote hippocampal cell injury
and death when chronically elevated,as in the setting of
hypercortisolemica associated with major depression.
Glucocorticoid-induced cellular damage may be mediated
through effects on several biochemical substrates.
Postulated mechanisms include decreased glucose uptake
and ATP generation,elevated intracellular calcium with
increased free radical production and degradative enzyme
activity, and impaired uptake of glutamate from hip-
pocampal synapses resulting in excitotoxicity.
28,37 In addi-
tion,hypercortisolemia has been linked to a decrease in
neurogenesis in the dentate gyrus.
38While the combination
of cell death and decreased neurogenesis may theoretically
contribute to hippocampal cell loss over time,recent evi-
dence suggests at most a minor role for this mechanism in
hypercortisolemic human subjects in the absence of co-
occurring insults.
39Animal and human studies support the
idea that glucocorticoids contribute to hippocampal atro-
phy and functional deficits predominantly through more
subtle alterations, including reduced synapse number,
40
atrophy of pyramidal cell dendrites,
41 derangement of glial
cells,
42 and other changes.
Neuroimaging studies have generally shown reduced hip-
pocampal volumes in late-life depression subjects rela-
tive to age-matched controls (See meta-analysis by
Videbech and Ravnkilde),
43 although this finding is not
universal.
44-46 Furthermore,many studies find a significant
association between hippocampal atrophy and greater
lifetime duration of depression,as assessed by number of
depressive episodes,
43 total days depressed,
30,47 total days
of untreated depression,
48 duration since first depressive
episode,
49 or early-onset as opposed to late-onset depres-
sion.
50 Although these findings differ somewhat, most
studies support to some degree the notion that depres-
sion-related hypercortisolemia can compromise hip-
pocampal structure and function,especially in the con-
text of old age and comorbid disease.
The impact of glucocorticoids on brain structures can be
expected to vary not only with age and disease status,but
also with individual genetic and environmentally-
imparted differences influencing hippocampal volume
and connectivity,HPA reactivity,and other neurobiologic
factors.
39,51 Besides the possibility of persistent synapse or
neuron loss induced directly by prolonged hypercorti-
solemia, glucocorticoid-related derangement of hip-
pocampal physiology,as described above,may increase
vulnerability to damage through other pathophysiologic
mechanisms.This latter effect may become clinically rel-
evant in older persons with co-occurring neuronal insults
such as accumulating AD pathology or cerebrovascular
disease,promoting synapse or neuron loss through a syn-
ergistic relationship with these factors.
The loss of hippocampal volume and memory function
observed in some elders with late-life depression suggests
the possibility that depression may be a predispositional
risk factor for AD in particular. Indeed, lower hip-
pocampal volumes independently predict subsequent
AD in groups of MCI and cognitively normal elderly
subjects.
52 Likewise,deficits in verbal learning and mem-
ory,similar to those described in euthymic patients with
history of major depression,
30 also predict AD (eg,ref 53).
While a primary causal role for depression in AD patho-
genesis seems unlikely,depression-associated hypercor-
tisolemia leading to decline in hippocampal size, con-
nectivity and cognitive function may represent one of
multiple links between depression and dementia as
described below (also see Figure 1).
Biologic relationships between depression and
Alzheimer’s disease 
The association between depression and dementia sug-
gested by epidemiologic data
10,11 may be partially
explained by one or more direct mechanistic links
between late-life depression-related processes and AD-
specific neuropathology (focal and diffuse cortical neu-
ronal loss, β-amyloid plaques, and neurofibrillary tan-
gles). Emerging evidence from neuroimaging studies,
postmortem neuropathologic analyses,and animal mod-
els provides support for such links.
Some structural magnetic resonance imaging (MRI)
studies find that hippocampal atrophy is more strongly
associated with late-onset than early-onset depression,
suggesting that early AD-related pathophysiology could
generate both hippocampal atrophy and depressive
symptoms in some elderly persons.
54,55 In addition,one of
these studies failed to find a significant correlation
between hippocampal volume and cortisol level among
elders with depression.Furthermore,the late-life depres-
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impairment at 6-month follow-up despite effective treat-
ment of mood symptoms and normalization of cortisol
levels.
55All of these data are consistent with the idea that
AD pathology is a major cause of hippocampal atrophy
in some (but not all) individuals with late-life depression,
and their depressive symptoms may represent prodromal
AD.
Several recent animal and human studies suggest a pos-
sible direct pathophysiologic link between late-life
depression and the neuropathologic hallmarks of AD.
Postmortem studies report greater hippocampal amyloid
plaque and neurofibrillary tangle pathology in AD
patients with lifetime history of depression compared
with those without such history,
56 and more severe cor-
tical neurofibrillary tangle pathology in the brains of AD
subjects who suffered from comorbid depression.
57The
hippocampal findings,combined with the observation of
marked hippocampal neurofibrillary pathology early in
the course of AD,
58,59 provoke speculation that depres-
sion-associated hypercortisolemia may facilitate AD
pathogenesis by rendering hippocampal neurons and glia
vulnerable to toxic insults,as discussed in the previous
section.
Neurobiologic interaction or overlap between late-life
depression and AD is further suggested by the discovery
of glial changes consistent with a CNS inflammatory
process in both older depressed individuals (eg,ref 60)
and those with neurodegenerative diseases such as AD.
61
The prolonged hypercortisolemia associated with both
diseases may partially account for these findings,as glu-
cocorticoids can induce proinflammatory changes within
the CNS.
62
Overall, these findings provide associational evidence
for a link between late-life depression and AD,yet offer
little insight into whether depression history may act as
a true etiologic risk factor for AD, or, conversely,
whether late-life depression arises secondary to AD-
related neuropathologic changes. However, two recent
animal studies suggest the existence of a direct mecha-
nistic link between hypercortisolemic depression and
AD pathology.
Green and colleagues
63 found dexamethasone adminis-
tration increased β-amyloid production in a transgenic
mouse model of AD,and traced this effect to increased
expression of amyloid precursor protein and the β-sec-
retase enzyme. This group also found increased tau
aggregation within neuronal cell bodies and dendrites of
dexamethasone-treated animals.Kang and colleagues
64
demonstrated increased hippocampal interstitial β-amy-
loid levels in another mouse model of AD following
acute restraint or chronic isolation stress.This finding was
reproduced through direct infusion of CRH into the hip-
pocampus, and blocked by pretreatment with CRH
antagonists.
In conclusion,diverse findings from structural MRI and
human or animal histopathologic studies suggest a direct
relationship between late-life depression and AD-spe-
cific pathology.Reports of a cross-sectional association
between later age of depression onset and hippocampal
atrophy
54,55 support the notion that early AD-related
pathophysiology is causing depressive symptoms in these
study groups and correlate with epidemiologic reports of
elevated dementia risk in subjects with depression onset
in the recent versus distant past (eg, refs 19,20).
Conversely,postmortem AD studies suggest an associa-
tion between more severe plaque and tangle pathology
and lifetime depression history preceding AD diagnosis,
56
offering support for the idea that prior depression is a
true,etiologic risk factor for AD,as suggested by other
epidemiologic data (eg,ref 11).Furthermore,both stress
and exogenous glucocorticoids increase β-amyloid pro-
duction in rodent models of AD,consistent with a direct
biologic role of human depression in AD pathogenesis.
These disparate hypothesized relationships are not exclu-
sive of one another.Given the tremendous heterogene-
ity of late-life depression,various dementia pathologies,
and the other clinical or subclinical disease inevitably
present in older individuals,depressive symptoms should
be expected to bear an inconsistent relationship with cog-
nitive decline,dementia in general,and AD specifically.
Such symptoms in a given elderly individual may poten-
tially represent either prodromal AD,or an independent
process interacting with AD-related pathophysiology.As
discussed in this manuscript,depression may furthermore
contribute to cognitive decline and AD through gluco-
corticoid-related hippocampal toxicity and interrela-
tionships with other types of pathology such as vascular
disease.
Role of vascular disease in late-life depression,
cognitive decline, and dementia
Substantial data exist showing an association between late-
life depression and cerebrovascular changes.In separate
reports,Alexopoulos
65 and Krishnan
66 pointed to the then-
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349nascent evidence that a subgroup of individuals with late-
life depression showed evidence of cerebrovascular
changes.Alexopoulos coined the term “vascular depres-
sion,”positing that a subgroup of individuals experience
disruption of prefrontal systems that mediate both mood
and executive functions,by either single vascular lesions
or accumulation of lesions.The concept of vascular depres-
sion has subsequently been supported and expanded by a
growing literature.Depression and vascular disease dis-
play an interesting bidirectional relationship.Depression
increases risk for first-ever myocardial infarction (MI) and
stroke,and has been shown to predict worse outcomes in
a wide range of concurrent vascular disease states
(reviewed in ref 67).Notably,clinical diagnosis of major
depression confers significant relative risk for MI,
68
stroke,
69 and post-MI cardiac mortality.
70,71 Moreover,
major depression confers greater relative risk than diag-
nosis of dysthymia or indices of self-reported depressive
symptoms,suggesting a possible dose-response relation-
ship between severity of depressive illness and excess car-
diovascular risk.
67
Diverse mechanisms have been proposed to explain the
link between prior depression and subsequent vascular
disease.
67,72,73 Depressed individuals exhibit poor treatment
compliance and other behaviors such as smoking, sub-
stance abuse,and inactivity,which may cause or worsen
comorbid disease.Depression is also associated with sys-
temic physiologic derangements which may contribute to
vascular pathology.As mentioned above,HPA axis dys-
regulation with hypercortisolemia is common in depressed
individuals.Elevated cortisol levels independently predict
several features of the metabolic syndrome including
abdominal obesity,low high-density lipoprotein (HDL)
levels, and hypertriglyceridemia.
74 They disrupt normal
endothelial function
75 and may contribute over time to the
development of hypertension in some cases.
76,77 Depressed
subjects with coronary artery disease (CAD) exhibit auto-
nomic dysfunction with decreased heart rate variability,
78
a condition that likely predisposes to both cardiac arrhyth-
mias and episodic hypoperfusion.Depressed individuals
with and without CAD show greater baseline platelet acti-
vation than nondepressed control subjects,
79-82 suggesting
greater susceptibility to thromboembolic events.Finally,
cross-sectional studies have linked depression to elevations
in proinflammatory cytokines.
83While the causal relation-
ship between such immunologic changes and depression
is unknown, a similar proinflammatory cytokine shift is
observed in atherosclerotic and thromboembolic disease
states.
84 C-reactive-protein is directly atherogenic,and high
levels of several proinflammatory cytokines have been
found to predict cardiovascular events.
85,86
In a reciprocal fashion,many acute and chronic vascular
disease states may promote depression. MI and stroke
substantially increase risk for depression during the imme-
diate postacute period,with depressive symptoms reported
in 25% to 50% of individuals (reviewed in ref 67). One
study comparing cumulative 1-year incidence of major and
minor depression immediately following stroke or MI
found no difference between these groups.
87This finding
suggests that the loss of specific neuronal populations is
less important than more global postischemic vascular or
inflammatory mechanisms in the pathogenesis of post-
stroke depression.Accordingly, depression is more fre-
quent and severe in vascular dementia than AD,
88 despite
widespread neuronal loss in both dementia syndromes.
Studies of individuals with chronic cardiovascular diseases
show that diabetes mellitus (see meta-analysis in ref 89)
and CAD,
90 each approximately double risk for depres-
sion.Many but not all studies of older subjects indicate a
longitudinal association between vascular disease/risk and
subsequent depression. Several prospective studies in
elderly subjects report that clusters of cardiovascular risk
factors or pre-existing CAD independently predict inci-
dent depression,while at least one large prospective study
found no relationship between an index of generalized
atherosclerosis and incident depression.
91 In old age,the
observed association between vascular disease and depres-
sion may be attenuated by the fact that persons with
severe or long-standing disease of either type incur sub-
stantial morbidity and mortality.Surviving individuals with
significant vascular or depressive pathology might actually
be expected to possess protective biopsychosocial factors
which interrupt the positive bidirectional relationship
described above.
Strong supporting evidence for the notion that vascular dis-
ease contributes to late-life depression comes from struc-
tural MRI studies showing a robust association between
ischemic brain lesions and depression diagnosis or self-
reported symptoms in older persons.
92 Large community-
based studies have demonstrated independent cross-sec-
tional relationships between late-life depression and small
basal ganglia lesions
93 and white matter abnormalities visu-
alized as hyperintense regions on T2-weighted MRI
(WMHs) in deep or subcortical areas.
94,95 Longitudinal stud-
ies suggest white matter changes may both predate and
independently predict late-life depression.
96,97
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The ischemic etiology of WMHs is suggested by several
lines of evidence,including post-mortem histopathologic
studies in patients with late-life depression
98,99 and in the
general population,correlating WMHs with both evidence
of cerebrovascular disease
100,101 and systemic hypotensive,
102
or hypoxemic disease.
101,103
Ischemic damage to frontostriatal brain regions may
explain the executive dysfunction,psychomotor slowing
and resistance to treatment common in late-life depres-
sion.
104The few studies examining WMHs and cognition in
late-life depression have found associations with psy-
chomotor slowing,
105,106 memory,language,and executive
functioning.
107,108 The relationship between WMHs and
executive function may be particularly strong in individu-
als with late-onset depression.
106,109,110Taken together,these
studies suggest a relationship among late-onset depression,
ischemic WMHs (especially in the frontostriatal region)
and executive dysfunction, raising the possibility that
ischemic structural changes in the brain are a common eti-
ologic factor of both the depression and the associated
cognitive dysfunction.
The cognitive impairment related to this ischemic damage
may be severe enough to culminate in a clinical diagnosis
of dementia.Vascular dementia,alone or in combination
with AD,occurs at high prevalence in the population (up
to 44% of all dementia).
111 In accordance with the bidirec-
tional relationship described here,prior depression inde-
pendently predicts subsequent vascular dementia (OR
=2.15
112) and individuals with late-life depression who
develop clinical AD have high rates of cerebrovascular
pathology upon postmortem examination.
1 Indeed,
prospective community-based studies report associations
between baseline systemic vascular disease/risk and both
higher rates of incident AD,
113 and more rapid cognitive
decline in established AD.
114 Moreover,rapid progression
of cerebrovascular disease as inferred from serial MRI
predicts subsequent dementia diagnosis.
115
In sum,mounting evidence suggests factors associated with
late-life depression may predispose to persistent cognitive
impairment and dementia.Plausible moderators of this
relationship include glucocorticoid-related hippocampal
damage,an interaction between depression and AD neu-
ropathology,and increased vascular disease,but the poten-
tial importance of other factors (eg,neurotransmitter and
immunologic abnormalities) cannot be excluded.
Moreover,in reality there appear to be abundant interac-
tions between the three distinct links described here and
depicted in Figure 1.Hypertension,for instance,is associ-
ated with diminished regional cerebral blood flow in the
hippocampus and related limbic and paralimbic structures
of cognitively normal older adults. Furthermore, MRI
assessments of cerebrovascular disease independently pre-
dict hippocampal atrophy.
116Together these findings sug-
gest ischemic and inflammatory insults related to cere-
brovascular disease may affect the same neuronal
populations endangered by hypercortisolemia and AD.
It is conceivable that hippocampal insults related to vas-
cular disease,hypercortisolemic depression or prodromal
AD which are insufficient to cause significant cellular
damage or death by themselves may produce cell death
through synergistic interaction with co-occurring insults.
In the context of neurodegenerative disease, cerebral
ischemia may contribute to cell death outside the hip-
pocampus, as suggested by an independent association
between WMH volume and cortical grey matter atrophy
in AD.
117 Notably,plasma levels of β-amyloid predict the
extent of ischemic white matter damage in MCI and AD,
118
suggesting a reciprocal interaction between cerebrovas-
cular and AD pathophysiology.Together these examples
suggest that particular combinations of insults arising from
different pathophysiologies may play a crucial role in pro-
moting cognitive decline and progressive dementia subse-
quent to depression,an effect related to extensive crosstalk
between links and synergism of insults at the cellular level.
Clearly,many factors influence the impact a particular risk
or disease factor will have on expression of dementia.In
the following section, we describe how the concepts of
brain and cognitive reserve can be used to explain this
multifactorial process and account for the highly variable
clinical course,cognitive course and neuropathology asso-
ciated with late-life depression.
Brain and cognitive reserve: 
the final common pathway 
linking depression to dementia
Brain and cognitive reserve are often used interchange-
ably, but in fact, have subtle but distinct differences in
meaning.
119 Nevertheless,either may account equally well
for the relationship between depression and dementia.
The concept of brain reserve capacity,first proposed by
Satz
120 varies across individuals such that those with
greater neuronal redundancy are able to tolerate more
cell loss than those with less redundancy, before mani-
festing clinical symptoms. The concept of redundancy
refers to the notion that circuits contain more than theminimum number of neurons needed to perform an
operation.Redundancy is evident when individuals incur
substantial neuronal loss before the appearance of clini-
cal symptoms.Thus, brain reserve capacity posits that
individual differences in neural redundancy translate into
differences in thresholds for vulnerability to or protec-
tion from clinical symptoms after brain damage.The con-
cept of cognitive reserve developed by Stern (eg, refs
121,122) is similar but rather than being based on differ-
ences in brain size or neuronal count,emphasizes differ-
ences in the efficiency or manner in which tasks are per-
formed or information is processed.
Both brain reserve and cognitive reserve explain the role
of risk and protective factors for cognitive impairment
(including progressive decline into dementia),associated
with brain damage. For example, higher educational
attainment,larger head size,larger brain volume,
123 social
engagement,
124 physical activity,
125 and leisure cognitive
activity
126,127 may result in greater redundancy and/or effi-
ciency and therefore reserve,thereby offering protection
against exhibiting clinical symptoms of dementia.
Similarly, lower levels of these protective factors may
reduce neuronal or functional redundancy leading to ear-
lier dementia symptom onset for a given level of CNS
damage.
While certain mechanisms may alter an individual’s risk
to develop (or change the rate of development of) AD-
related pathology (eg, β-amyloid deposition), other
mechanisms alter the strength of association between
these biological changes and the time to develop clini-
cal disease.We propose that depression alters an indi-
vidual’s risk of cognitive dysfunction, shortening the
latent period between the development of AD neu-
ropathology and the onset of clinical dementia, thus
increasing the incidence and prevalence of AD among
older adults with depression.
Proposed multiple pathways model
We propose that the reserve threshold theory is the key
explanatory mechanism behind the late-life depres-
sion/dementia association.That is,through a number of
processes (several described here), depression injures
neurons, thus lowering reserve such that cognitive
impairment is expressed earlier and/or more frequently
than it would otherwise.As depicted in Figure 1,depres-
sion is linked to vascular disease,especially in the fron-
tostriatal area.Depression also is linked to elevated glu-
cocorticoid production,as well as amyloid deposition and
neurofibrillary formation,each of which may lead to hip-
pocampal injury.Each of these processes adds to the total
brain injury burden,lowering reserve and vulnerability
to express cognitive impairment.
These links and processes are not mutually exclusive;
many are likely synergistic, so that they act to varying
degrees across groups of individuals.This accounts for the
substantial heterogeneity of the mood disorder and the
presence (or absence) of a cognitive disorder and its clin-
ical course.For example,it is possible that the diminished
hippocampal volume identified in group studies could be
the result of more than one underlying process.
Individuals with early-onset,recurrent depression may
have hippocampal volume loss due to the repeated stress
associated with multiple depressive episodes.Many indi-
viduals with later-onset depression may be in the pro-
dromal stage of AD, their hippocampi having already
sustained substantial neuronal injury due to cumulative
AD neuropathology.
There may be additional pathologic processes,indepen-
dent of depression,which can affect cognition.For exam-
ple, amyloid plaques and neurofibrillary tangles com-
monly accumulate in aging brains,
123,128-130 and it is likely
that in some cases AD pathology represents an indepen-
dent,co-occurring process (ie,depression is the first man-
ifest symptom of AD).Vascular disease accompanying
AD pathology in the absence of depression, promotes
cognitive decline and an earlier expression of dementia
(eg,refs 111-115,131).In fact,the growing evidence that
AD and cerebrovascular pathology co-occur with high
frequency has led some to conclude that the strict dis-
tinction between AD and vascular dementia is artificial.
131
Social isolation,
124 physical inactivity,
125 and lack of leisure
cognitive activity
126,127 may result in lowered reserve and
therefore confer additional risk for exhibiting clinical
symptoms of dementia. Moreover, late-life depression
frequently occurs in the context of chronic medical ill-
ness,and major organ system dysfunction is frequently
associated with cognitive impairment,
132 acting to further
lower reserve.
Thus, each of the processes mentioned above and
depicted in Figure 1, independently adds to the total
brain injury burden,lowers reserve,and strengthens the
association between the neurodegenerative process and
the clinical change in cognitive functions.We believe that
this explanation underlies the relationship between late-
life depression and dementia in general,and AD in par-
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352ticular (see Figure 1).This conceptualization de-empha-
sizes the importance of the distinctions between early
and late-onset depression and the relative risk for AD
vs vascular dementia in the context of late-life depres-
sion.The cognitive outcome of any given individual who
has late-life depression depends largely on the predom-
inance or particular mix of pathophysiology in that indi-
vidual.The additive or synergistic effects of vascular dis-
ease, glucocorticoid-related brain injury, and intrinsic
AD pathophysiology are reflected in the empirical find-
ings of heterogeneous neuropathology in late-life
depression and dementia.
1 This framework, by focusing
on the key concept of reserve threshold, delineates
testable (and falsifiable) links between depression and
subsequent dementia.
Figure 2 depicts various pathways through which the key
processes outlined in Figure 1 may lead to the heteroge-
neous cognitive and disease outcomes reported in the lit-
erature.The pathways include (in order of figure presen-
tation):(i) Individuals who develop depression at any point
in their lives,sustain minimal or no depression-related neu-
ropathology (eg,glucocorticoid neurotoxicity),and who
have stable,normal cognitive functioning;(ii) Individuals
who develop depression at any point and who experience
depression-related neuropathology that results in MCI that
is stable (unless they experience additional depressive
episodes); (iii) Individuals who accumulate AD neu-
ropathology over many years and who develop late-life
depression (related or unrelated to AD pathology),that
lowers brain reserve capacity,and results in expression of
MCI earlier than otherwise would be the case,and given
the underlying neuropathology, progress to AD; (iv)
Individuals who accumulate AD neuropathology over
many years along with co-occurring cerebrovascular dis-
ease,which damages the frontostriatal circuitry,leading to
late-life depression. The total neuropathologic burden,
combined with depressed mood, lowers brain reserve
capacity,leads to expression of MCI (eg,memory and exec-
utive dysfunction) earlier than otherwise would be the case,
and,given the underlying neuropathology,progresses to
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Figure 2. Pathways linking depression to predominant cognitive outcomes. MCI, mild cognitive impairment; AD, Alzheimer's disease; CVD, cerebro-
vascular disease.
Depression
Depression
Normal cognition Normal cognition
Stable over time
1
Depression
Depression-associated neuropathology
(eg, hippocampal volume loss)
Stable MCI MCI
Stable over time
2
Depression
AD neuropathology (eg, hippocampal volume loss)
AD MCI
Progression over time
3
CVD
AD neuropathology
Frontostriatal damage
+
Hippocampal volume loss
AD
+
CVD MCI
Progression over time
4
Depression
CVD Frontostriatal damage
Vascular dementia MCI
Progression over time
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Vías que relacionan la depresión de 
aparición tardía con el deterioro cognitivo
persistente y la demencia
Existe una fuerte asociación entre la depresión de
aparición tardía, el deterioro cognitivo, la enferme-
dad cerebrovascular y los desarrollos cognitivos des-
favorables, incluyendo la demencia progresiva, espe-
cialmente la Enfermedad de Alzheimer. Aunque la
evidencia de las neuroimágenes sugiere que la enfer-
medad cerebrovascular tiene un papel preponde-
rante, parece que la depresión por sí misma también
puede conferir un riesgo considerable para el desa-
rrollo de la Enfermedad de Alzheimer. Ha sido difícil
conciliar en los pacientes con depresión de aparición
tardía las relaciones entre los marcados cambios cere-
brovasculares, otras anormalidades estructurales, for-
mas específicas de la disfunción cognitiva y el
aumento del riesgo para desarrollar la Enfermedad
de Alzheimer. Los variados hallazgos sugieren que
probablemente existen múltiples caminos para los
desarrollos cognitivos desfavorables. Nosotros pre-
sentamos un esquema que resume múltiples víncu-
los etiológicos no mutuamente excluyentes entre la
depresión, el deterioro cognitivo y el decaimiento
progresivo, incluyendo la demencia. Es importante
considerar que el modelo puede ser aprobado o
refutado. A futuro, la utilización de modelos como
éste para dar cuenta de las investigaciones debería
acelerar la adquisición de conocimientos sobre la
relación entre depresión y demencia que pueda ser
útil para la prevención de la demencia y para moni-
torear el impacto del tratamiento de la depresión en
el estado clínico y en el curso de la enfermedad.
Liens entre la dépression du sujet âgé et le
déficit cognitif persistant et la démence
Il existe une forte association entre la dépression du
sujet âgé, le déficit cognitif, la maladie cérébrovas-
culaire et les faibles performances cognitives,
incluant la démence progressive, et en particulier la
maladie d’Alzheimer. Alors que la neuro-imagerie est
en faveur d’un rôle majeur de la maladie cérébro-
vasculaire, la dépression seule pourrait représenter
un risque substantiel de développer une maladie
d’Alzheimer. Il est difficile de trouver un lien chez les
sujets âgés atteints de dépression entre les modifi-
cations cérébrovasculaires marquantes, les autres
anomalies structurales, les formes spécifiques de dys-
fonction cognitive et un risque augmenté de déve-
lopper cette maladie. L’existence de  résultats variés
laisse supposer que les voies menant aux faibles per-
formances cognitives sont nombreuses. Cet article
présente divers liens étiologiques, non exclusifs
mutuellement, entre la dépression, le déficit cogni-
tif et le déclin progressif, y compris la démence. Il
faut noter que ce modèle est à la fois testable et
réfutable. En outre, l’utilisation de ce type de modè-
les, qui enrichissent la recherche, devrait accélérer
l’acquisition des connaissances sur les liens dépres-
sion/démence, ce qui pourrait être utile à la préven-
tion de la démence, surveillant l’effet du traitement
de la dépression sur l’état clinique et l’évolution de
la maladie.
AD along with co-occurring cerebrovascular disease;and
(v) Individuals who develop cerebrovascular disease (with
variable neuropathologic burden),that damages the fron-
tostriatal circuitry,leading to late-life depression and MCI
(eg,executive dysfunction),that will follow the course of
the underlying cerebrovascular disease. Based on the
weight of the findings in the published literature and con-
sistent with our model depicted in Figure 1,we suggest that
Pathway #4 (Figure 2) leading to AD with co-occurring
cerebrovascular disease is the most frequently occurring
pathway among individuals with late-onset depression.
Understanding the pathways through which individuals
with late-life depression develop progressive dementia
in general,and AD in particular,is critical as novel treat-
ment may prevent,forestall,or slow cognitive and/or dis-
ease progression. ❏
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